JERUSALEM, Oct. 31, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that it will be showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO services at the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden.

Scinai's CEO, Mr. Amir Reichman, and CTO, Dr. Dalit Weinstein-Fischer will be holding meetings during the conference days with:

• Prospective clients of the company's end-to-end biologics CDMO services.
• Potential pharma partners in the field of I&I interested in co-developing or in-licensing one of Scinai's innovative NanoAbs.
• Potential pharma partners in the field of dermatology interested in Scinai's drug development program for local treatment of mild to moderate plaque psoriasis – "the Botox-like solution for psoriatic patients"
• Institutional and private investors interested in SCNI's value proposition.

Additional interested parties are encouraged to schedule a meeting through the conference partnering platform or to email Scinai at [email protected] to schedule a meeting. Throughout the conference, Scinai will also be available at exhibitor booth #150 to showcase its CDMO services.

About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. Company website: .

Company Contacts
Investor Relations | +972 8 930 2529 | [email protected]
CDMO and Partnering | +972 8 930 2529 | [email protected]

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that the Scinai will not be able to sign agreements with other potential clients of the CDMO business; lower than anticipated revenues of Scinai's CDMO business in 2024 and thereafter; a delay in the commencement and results of pre-clinical and clinical studies; the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that Scinai's business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other treatment technologies; the risk that drug development involves a lengthy and expensive process with uncertain outcomes; and the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq;. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 15, 2024, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo:

SOURCE Scinai Immunotherapeutics Ltd.